ArticleEClinicalMedicine2024
Effectiveness and safety of tetracyclines and quinolones in people with
Article in EClinicalMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 19 citations in OpenAlex.
- Article
- Research progress and trends of Mycoplasma pneumoniae pneumonia in children: a bibliometric and visualization analysis (1990s to post-COVID-19 era).Pediatric research · 2026Article
- Population pharmacokinetics and exposure-response analysis of levofloxacin in Chinese pediatric patients with severe refractoryAntimicrobial agents and chemotherapy · 2026Article
- Targeted next-generation sequencing reveals pathogen spectrum, drug resistance characteristics, and clinical determinants in children with community-acquired pneumonia.Translational pediatrics · 2026Article
- Article
- Qingfei Tongluo Jiedu Formula Regulates M2 Macrophage Polarization via the Butyric Acid-GPR109A-MAPK Pathway for the Treatment ofPharmaceuticals (Basel, Switzerland) · 2026Article
- A case of severeRespiratory medicine case reports · 2026Article
- A Novel Nomogram Integrating Clinical, Radiological, and Immunological Indicators for Early Prediction of SevereJournal of inflammation research · 2026Article
- Clinical value of neutrophil-to-lymphocyte ratio and D-dimer in predicting the efficacy of minocycline for pediatric Mycoplasma pneumoniae pneumonia.Frontiers in pediatrics · 2026Article
- Research progress on the current status of respiratory pathogen infections and their detection methods.Frontiers in microbiology · 2026Review
- Influence of Mycoplasma Resistance Genes on Pediatric Mycoplasma Pneumonia Treatment and Determinants for Second-line Antimicrobial Adjustment.Combinatorial chemistry & high throughput screening · 2026Article
- Resurgence of Mycoplasma pneumoniae infections in children: emerging challenges and opportunities.Current opinion in infectious diseases · 2025Review
- Fulminant Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in a Young Adult: A Case Report.Cureus · 2025Article
- A comparison of diagnostic and therapeutic approaches for Mycoplasma pneumoniae pneumonia in children and adults, during the post-COVID-19 pandemic era.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Epidemiology, Characteristics, and Treatment Outcomes ofOpen forum infectious diseases · 2025Article
- Genetic factors driving theThe Lancet regional health. Western Pacific · 2025Article
- Mycoplasma pneumoniae-Induced Erythema Multiforme in an 11-Year-Old Boy: Diagnostic and Therapeutic Challenges.Cureus · 2025Article
- Epidemiological and clinical characteristics of hospitalized pediatric patients with Mycoplasma pneumoniae pneumonia before and after the COVID-19 pandemic in China: a retrospective multicenter study.BMC infectious diseases · 2025Article
- Efficacy and safety of combined Linggui Bafa Tui Na and Fuxiong San herbal powder therapy in pediatric Mycoplasma pneumonia.American journal of translational research · 2025Article
- Atelectasis predicts poor prognosis in pediatric macrolides-unresponsiveFrontiers in cellular and infection microbiology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The escalating resistance of Methods: In this systematic review and network meta-analysis we searched PubMed, Embase, CNKI, and WanFang Data, from inception up to November 11th, 2023. Studies of quinolones or tetracyclines for the treatment of people with Findings: The systematic review and direct meta-analysis included a total of 4 articles involving 246 patients, while the NMA encompassed 85 articles involving a substantial cohort of 7095 patients. The NMA measured the effectiveness across all ages and included 7043 patients, with a mean age of 37.80 ± 3.91 years. Of the 85 included studies, 14 (16.5%) were at low risk of bias, 71 (83.5%) were at moderate risk, and no studies were rated as having a high risk of bias. In the direct meta-analysis, no statistically significant differences were found between tetracyclines and quinolones concerning TTD (mean difference: -0.40, 95% CI: -1.43 to 0.63; Interpretation: Our findings suggest that tetracyclines and quinolones may be equally effective. Based on the age of participants in the included studies, minocycline may be the most effective intervention for children over eight years of age when all preventive measures are considered, whereas moxifloxacin may benefit people under eight years of age. However, these results should be interpreted with caution, given the limited number of studies and patients included, and the heterogeneity between included studies. Based on a limited number of studies in children, levofloxacin is likely to have one of the highest rates of adverse reactions. The majority of the studies included in the NMA were from the Asian region, and more randomised controlled trials comparing different therapeutic strategies in patients with Funding: The Natural Science Foundation of Fujian Province, China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.